Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 37: Line 37:
  
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.05.docx | QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey}]] ''April 5, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.05.docx | QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey}]] ''April 5, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.21.some spring cleaning.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 21, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.16.some tracked changes-yuni.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Dewaraja}]] ''March 16, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.16.some tracked changes.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 16, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.16.docx | QIBA DRAFT Profile - {Dr. Miyaoka}]] ''March 15, 2016''
 
 
*[[Media:Draft Profile Section on Image Analysis 3.10.docx | QIBA DRAFT Profile Section 3.10 on Image Analysis - {Drs. Miyaoka and Seibyl}]] ''March 8, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.02.17.docx | QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease - {comments from Mr. Cella}]] ''February 17, 2016''
 
  
 
*[[Profile drafts|Archived past versions of the Profile]]
 
*[[Profile drafts|Archived past versions of the Profile]]
 
  
 
==Reference Materials==
 
==Reference Materials==

Revision as of 20:26, 17 March 2017

Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD
Secretary: Julie Lisiecki
Roster: (Roster)

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.

Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases

Established Task Forces currently working toward a first Profile titled:

Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Meetings/Call Summaries

Literature Review (Profile 1.0)

Profile Development

Reference Materials